On February 21, 2017, the Ministry of Human Resources and Social Security officially issued the Notice on Printing and Distributing the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition), clearly requiring all provinces (autonomous regions and municipalities) to be required on July 31, 2017. Recently, the list of local basic medical insurance, work injury insurance and maternity insurance drugs has been released. Now, the deadline has passed and the progress of the supplementary catalogues in various places has progressed.
9 provinces and municipalities officially issued a draft for comments
Up to now, 9 provinces and cities including Qinghai, Shanxi, Hubei, Guizhou, Ningxia, Sichuan, Hainan, Jilin, and Beijing have issued medical insurance catalogue supplements (draft for comments), of which Qinghai Province is the first national medical insurance catalogue. It is worth noting that the provinces of the adjustment plan are the only provinces that have transferred the varieties in the 2009 edition of the province (5 varieties, including 4 western medicines and 1 Chinese medicine).
In addition to the above nine provinces and cities, there are several provinces in the upcoming “release†stage, including Anhui Province, Guangdong Province and Hunan Province. Recently, the Anhui Provincial Department of Human Resources and Social Security issued the “Regulations on the implementation of national basic medical insurance, work injury insurance and childbirth. Notice of the Insurance Drugs Catalogue (2017 Edition) (hereinafter referred to as the Notice), the "Notice" indicates that the supplement of the new drug list related drugs in Anhui Province is still in progress, before the catalogue is officially released, from September 1 All the national version catalogues are uniformly implemented, and the drugs in the Anhui Provincial (2010 edition) catalogue that are not included in the 2017 edition of the National Basic Medical Insurance Drug List continue to be used, which means that medicines that have not entered the national catalog in the old catalogue can be retained. As for when the supplementary catalogue will be completed and released, it is not mentioned in the notice.
In Guangdong Province, in the official website of the People's Social Welfare Department, the relevant questions on medical insurance supplements were replied and publicized. The state negotiating varieties entered the local supplementary situation and the addition of Guangdong medical insurance catalogues in recent years have a more detailed reply.
In its recent implementation of the health development of the pharmaceutical industry, Hunan Province clearly stated that it will give priority to the enterprises in the province, and set up a “provincial supplementary catalogue through trainâ€. For the province’s production of the same name, it will also refer to the existing products in the relevant catalogue. Incorporate or add relevant specifications and dosage forms into the relevant provincial-level catalogues.
Fujian and Beijing are not added?
Especially worth mentioning is the province of Fujian Province, the province of medical reform. On June 5, 2017, the Office of the Medical Security Management Committee of Fujian Province officially issued the Notice of Forwarding the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drugs Catalogue (2017 Edition). The main content is to forward the National Medical Insurance Catalogue (2017 version), which is required to be used in conjunction with the relevant regulations on medical insurance payment in Fujian Province.
This means that the Fujian medical insurance catalogue is not supplemented, directly using the national catalogue, a stone stirs up a thousand waves! This news can be said to have exploded in the industry circle, there is a voice helplessly said: has not begun to add, Fujian has closed the door in advance. However, some people in the industry think that it is not the case. The notice does not mention the fact that the provincial level does not add up. Of course, there is no mention of provincial supplementary matters. From the point of view of metaphysics, if you only think that the Fujian provincial level is not added, it is a bit biased.
The same situation still exists in Beijing. On July 25th, Beijing issued a document to the public on the “2017 Beijing Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue Adjustment Work Plan (Draft for Comment)â€. On the 1st, the deadline for soliciting opinions, compared with the 8 provinces and cities that have published the draft for comments, the drafts of these provinces have clearly defined the number of adjustments, and explicitly mentioned the words “tune inâ€, even the simplest Sichuan. The province also indicated in the adjustment content that according to the [2017] No. 15 regulation issued by the Ministry of Human Resources and Social Security, the Class A drugs are no longer adjusted, and the number of Class B drugs is adjusted (including the transfer, transfer, and adjustment of the limited payment range). ) must not exceed 15% of the national B drugs, or 291 species. However, there is no such content in the Beijing plan. It is only clear that the drugs added in the 2017 national medical insurance catalogue are all entered into the Beijing medical insurance catalogue, and the national medical insurance negotiating varieties are entered into the Category B catalogue as required. At the same time, it has been retained in the Beijing Medical Insurance Catalogue, except for those drugs that have been banned from production, sale and use by the national drug regulatory authorities and that do not meet the medical insurance requirements and conditions. Does this mean that the Beijing Medical Insurance Catalog will not be added?
Some analysts believe that this is unlikely in the above round of Beijing's supplementary number, but it is not clear. In addition, unlike other provinces, Beijing may adjust for the scope of medical insurance payment in the new national medical insurance catalogue.
What are the similarities and differences between different places?
According to the current local medical insurance catalogue adjustment plan that has been introduced in various provinces, many similarities and differences can be found in the transfer and transfer policy.
Transfer: It has been included in the catalogue of the province, and the products widely used by medical institutions and the “reasonable price†are preferred. Varieties of endemic diseases, frequently-occurring diseases, common diseases and disease spectrum requirements of various provinces, as well as medical treatment funds for major diseases, medicines for children, emergency medications, occupational diseases, etc., as well as medical insurance catalogues that have entered various provinces and cities. For example, Qinghai, Sichuan, Guizhou, Hainan and Hubei will give priority to the varieties that have been included in the previous edition of the medical insurance catalog but not included in the 2017 National Drug List and need to be retained. Shanxi will give priority to the varieties that have been included in the 2010 Shanxi Medical Insurance Drug List, the 2011 New Rural Medicines List, and the 2012 Essential Medicines List.
Recall: drugs that have not been produced, sold or used by the State Food and Drug Administration for non-existence in the registration database of the State Food and Drug Administration; drugs that are not covered by medical, industrial injury, maternity insurance and medical treatment items Drugs in the range of charges, etc.
Whether the unsuccessful varieties of negotiations are included in the supplementary: Qinghai, Shanxi, Hainan, Jilin, and Hubei provinces clearly stated that the varieties that have not been successfully negotiated with the Ministry of Human Resources and Social Security are not included in the supplementary list.
Whether the scope of payment is adjusted: Qinghai, Shanxi, Ningxia, Sichuan, Guizhou, Hainan, Jilin, and Hubei provinces clearly stated that there will be no adjustments to the limited payment range in the national drug list, and Beijing may make adjustments.
SARS-CoV-2 IgM/IgG Duo Test (Colloidal Gold)
SARS-CoV-2,IgM/IgG Duo,SARS-CoV-2 antibody,COVID-19 antibody,Colloidal Gold
Shenzhen Uni-medica Technology Co.,Ltd , https://www.unimedicadevice.com